INGENIA Therapeutics is a research-driven biotechnology company.

We are committed to the discovery and development of advanced therapeutics for patients afflicted by inflamed and leaky blood vessels.

We use our deep knowledge and commitment to endothelial biology to innovate and find new solutions where none exist.

We focus on the treatment of damaged small vessel-associated diseases with high unmet clinical needs.
INGENIA builds on strategic research partnerships with major pharmaceutical companies for research and development activities to deliver human proof of concept studies.

We aim to be a global leader in developing next-generation therapeutics to protect and restore the microvasculature.